Angiotensin-neprilysin inhibition versus enalapril in heart failure.
By J. McMurray, M. Packer, Akshay S. Desai, J. Gong, M. Lefkowitz, A. Rizkala, J. Rouleau, V. Shi, S. Solomon, K. Swedberg and 1 more. New England Journal of Medicine, 2014
6,025 citations recorded by the source corpus.
BACKGROUND We compared the angiotensin receptor-neprilysin inhibitor LCZ696 with enalapril in patients who had heart failure with a reduced ejection fraction. In previous studies, enalapril improved survival in such patients. METHODS In this double-blind trial, we randomly assigned 8442 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive either LCZ696 (at a dose of 200 mg twice daily) or enalapril (at a dose of 10 mg twice daily), in addition to recommended therapy. The primary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure, but the trial was designed to detect a difference in the rates of death from cardiovascular causes. RESULTS The trial was stopped early, according to prespecified rules, after a median follow-up of 27 months, because the boundary for an overwhelming benefit with LCZ696 had been crossed. At the time of study closure, the primary outcome had occurred in 914 patients (21.8%) in the LCZ696 group and 1117 patients (26.5%) in the enalapril group (hazard ratio in the LCZ696 group, 0.80; 95% confidence interval [CI], 0.73 to 0.87; P<0.001). A total of 711 patients (17.0%) receiving LCZ696 and 835 patients (19.8%) receiving enalapril died (hazard ratio for death from any cause, 0.84; 95% CI, 0.76 to 0.93; P<0.001); of these patients, 558 (13.3%) and 693 (16.5%), respectively, died from cardiovascular causes (hazard ratio, 0.80; 95% CI, 0.71 to 0.89; P<0.001). As compared with enalapril, LCZ696 also reduced the risk of hospitalization for heart failure by 21% (P<0.001) and decreased the symptoms and physical limitations of heart failure (P=0.001). The LCZ696 group had higher proportions of patients with hypotension and nonserious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enalapril group. CONCLUSIONS LCZ696 was superior to enalapril in reducing the risks of death and of hospitalization for heart failure. (Funded by Novartis; PARADIGM-HF ClinicalTrials.gov number, NCT01035255.).
Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism
View Paper: https://www.semanticscholar.org/paper/9ca73cac94d6c53f5e6f821c7e013aa604221784
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Endocrinology, Diabetes and Metabolism
Citations in the corpus
- Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets (2015, background): “More recently, the dual angiotensin–neprilysin receptor inhibitor has been shown to be more effective than the current standard treatment (the ACE inhibitor enalapril) at preventing the progression of HF (McMurray et al. 2014; Packer et al. 2015).”
- Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology (2018, methodology): “In the PARADIGM-HF trial, sacubitril/valsartan was superior to ACE-inhibitor, enalapril, in reducing the risks of death and HF hospitalization (primary endpoint) in patients with HFrEF (50).”
- 2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy. (2019, background): “The 2016 recommendations of the AHA/ACC(7) and ESC guidelines(9) include new drugs: the angiotensin receptor-neprilysin inhibitor (valsartan/sacubitril(193)) and the sinoatrial modulator, ivabradine.(193,194) The therapy for congestive symptoms includes loop diuretics and volume control, with recomm”